26 May 2013
Keywords: gsk, enters, global, trx4, alliance, tolerx, uk
Article | 29 October 2007
UK drug major GlaxoSmithKline and USA-based Tolerx have entered a worldwide alliance to develop and commercialize otelixizumab (TRX4), a novel ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.